The post-market phase is the phase following the placement of medical devices on the market. ISO 14971 also refers to the post-production phase after development and production.
Content
This page provides a quick overview of the articles on the post-market phase:
The post-market or post-production phase comprises all activities after production until the decommissioning/decommissioning of the devices, at the latest, at the end of their service life. These activities also include use and maintenance.
Fig. 1: The post-market phase is an important part of the product life cycle.
The international regulatory requirements for the post-market phase are increasing. The EU MDR and IVDR regulations are evidence of this. In addition, there are national regulations, such as 21 CFR part 822 on post-market surveillance, and national laws and regulations on vigilance, such as the German law MPAIMV.
There are also guidelines, such as MDCG 2022-21 and MDCG 2020-6, and laws that apply to all devices, such as the Product Liability Act, which also requires post-market activities such as monitoring.
The regulations oblige manufacturers to carry out post-market surveillance, for example. To this end, manufacturers must draw up a post-market surveillance plan and collect and evaluate the post-market surveillance data in accordance with this plan. Manufacturers find it particularly difficult to analyze trends. The output then flows into reports such as the Periodic Safety Update Report (PSUR).
Depending on the class of the devices, the reports must also be published in EUDAMED.
One part of post-market surveillance is the post-market clinical follow-up (PMCF). This involves collecting clinical data to keep the clinical evaluation up to date. If the data is insufficient, PMCF studies may be necessary.
If serious incidents or trends leading to an unacceptable risk are observed in the post-market phase, manufacturers must notify the authorities (vigilance) and take corrective action.
Post-market activities include monitoring new regulations (regulatory update), monitoring vulnerabilities in off-the-shelf software, and eliminating these vulnerabilities with security patches.
These activities are not only the responsibility of manufacturers, for example, their product managers, quality management representatives, medical device consultants, and responsible persons.
Suppliers, importers, and distributors also have obligations in this post-production phase.
The essential objective of all these activities is to ensure patient safety, i.e., to minimize risks from unsafe devices.
For this reason, the third edition of the risk management standard ISO 14971 has increased the requirements for the post-production phase. The associated Technical Report ISO/TR 24971 describes these requirements in more detail.
To assess the benefit-risk ratio, manufacturers must continuously monitor and consider the state of the art.
Not doing so is one of the most common mistakes in risk management.
Do you still have questions about the post-market phase? Then, take advantage of our free micro-consulting.
If you want to delve deeper into the topic, we offer video training courses at the Medical Device University.
The post-market services take a large part of the work off your hands, from monitoring the regulations to post-market surveillance. This enables you to achieve:
Contact us if you would like support.
Anytime you want to launch a medical device on the market, you quickly come to the question of which legal regulations you have to comply with. This article will give you answers and present the seven steps to quickly place your devices on the market in compliance with the law. Step 1: Determine if the…
DetailsThis article identifies the seven most common risk management errors that Johner Institute and its auditors encounter most often. It also offers advice on how to avoid these errors. Risk management is among the most important requirements medical device manufacturers must meet. Therefore, it is important that they avoid risk management errors. 1st error class:…
DetailsThe terms maintenance, preventive maintenance, restoration, inspection, service, and safety inspections are not synonymous. But they all refer to activities in the life cycle of medical devices that serve the objective of ensuring the safety, performance, and effectiveness of these devices even after they have been placed on the market. Manufacturers and operators must meet…
DetailsThe MDR and IVDR require either a “Post-Market Surveillance Report” or a “Periodic Safety Update Report” from medical device manufacturers. The Periodic Safety Update Report is abbreviated as “PSUR”, the Post-Market Surveillance reports as “PMS report”. PSUR and PMS report: Regulatory background and objectives The European Commission has significantly increased the requirements for monitoring devices…
DetailsThe MDR requires medical device manufacturers to conduct Post-Market Surveillance (PMS) and thus collect PMS data. This article is intended to help clarify the regulatory requirements manufacturers must consider when collecting these PMS data. Notably, it is intended to highlight whether manufacturers need to consult an ethics committee in Europe if the data arise from…
DetailsPost-Market Surveillance (PMS) is a proactive and systematic process to derive necessary corrective and preventive actions (CAPA) from information about medical devices already placed on the market. We have created a Post-Market Surveillance checklist for you. With this checklist, you can find out whether you meet the regulatory requirements of the MDR for Post-Market Surveillance…
DetailsThe medical device regulations have significantly increased the requirements for distributors. You need to understand these requirements to avoid multi-year custodial sentences threatened in the event of infringement. This article also considers extensive guidance issued by the Irish regulator. 1. What a “distributor” is (and what it isn’t) a) Definition The Medical Device Regulation (MDR) has many…
DetailsManufacturers of substance-based medical devices such as seawater nasal sprays, mucous membrane-soothing cough syrups, or osmotically active laxatives face several challenges once the Regulation (EU) 2017/745 (MDR) came into force: This article illustrates what can be done to overcome the regulatory hurdles and ensure the marketability of your substance-based medical devices beyond the transition…
DetailsWith the Post-Market Surveillance plan (PMS plan), manufacturers are trying to achieve two (potentially) contradictory goals. On the one hand, they have to comply with the legal requirements and maximize the safety of their devices. And on the other, they can only take on as much work as they can realistically do in the long…
Details